Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacytidine Priming Prior to FLAG in Relapsed/Refractory AML
NCT02275663Phase 2Unknown
- Sponsor
- King Fahd Medical City
- Start
- Dec 2014
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), sponsored by King Fahd Medical City. Status: unknown.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02275663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275663.